Brainstorm Cell chair receives 900K stock options

Q: What are the key terms of Peter Joe Pitts’ BCLI stock options?

Peter Joe Pitts’ options cover 900,000 common shares at a $1.00 exercise price and expire on July 24, 2036. The grant is structured as a long-term incentive under the 2014 Stock Incentive Plan, aligning potential value with company performance over time.

Q: How do the BCLI options granted to Peter Joe Pitts vest over time?

The options vest over 48 months, with 25% vesting on July 24, 2027 and the remaining 75% vesting in 1/48th increments monthly. Vesting is conditioned on Peter Joe Pitts remaining employed through each applicable vesting date.

Q: How many BCLI derivative securities does Peter Joe Pitts hold after this grant?

After this transaction, Peter Joe Pitts holds 900,000 stock options linked to Brainstorm Cell Therapeutics common stock. This reflects the full amount of the new grant, as the report shows 900,000 derivative securities owned following the award.

Q: What type of security is involved in the recent BCLI insider transaction?

The transaction involves a Stock Option (Right to Buy) derivative security linked to Brainstorm Cell Therapeutics’ common stock. Each option grants the right to purchase one common share at $1.00, subject to the vesting schedule and expiration terms.

Brainstorm Cell Therapeutics Inc. reported that Executive Chairman Peter Joe Pitts received a grant of 900,000 stock options on July 24, 2026.

Accepted by SEC EDGAR 07/28/2026 - 05:00 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Brainstorm Cell Therapeutics Inc. reported that Executive Chairman Peter Joe Pitts received a grant of 900,000 stock options on July 24, 2026. The options have a $1.00 exercise price, are exercisable for 900,000 common shares, expire on July 24, 2036, and vest over 48 months subject to continued employment.

Insider Trade Summary

Grant/Award: 900,000 shares

Grant/Award 1 txn

Insider Pitts Peter Joe

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^{F1, F2}	900,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 900,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 900,000 contracts (Direct)

Footnotes (2)

F1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
F2. The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Stock options granted: 900,000 options Exercise price: $1.00 per share Underlying common shares: 900,000 shares +4 more

7 metrics

Stock options granted 900,000 options Grant to Executive Chairman Peter Joe Pitts on July 24, 2026

Exercise price $1.00 per share Per-share exercise price for the granted stock options

Underlying common shares 900,000 shares Number of common shares underlying the option grant

Expiration date 2036-07-24 Date on which the options expire if unexercised

Vesting period 48 months Total period over which the granted options vest

Initial vesting portion 25% Portion of options vesting on July 24, 2027

Ongoing monthly vesting fraction 1/48th Fraction of the grant vesting monthly after July 24, 2027

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vest over 48 months, underlying security

4 terms

Stock Option (Right to Buy) financial

"The security title is listed as "Stock Option (Right to Buy)"."

2014 Stock Incentive Plan financial

"Granted under the Issuer's 2014 Stock Incentive Plan."

vest over 48 months financial

"The stock options vest over 48 months, with 25% vesting on July 24, 2027"

underlying security financial

"The underlying security title is Common Stock with 900000.0000 shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award did BCLI grant to Executive Chairman Peter Joe Pitts?

Brainstorm Cell Therapeutics granted Executive Chairman Peter Joe Pitts 900,000 stock options to buy common shares at $1.00 per share. These options expire on July 24, 2036 and were issued as compensation under the company’s 2014 Stock Incentive Plan.

What are the key terms of Peter Joe Pitts’ BCLI stock options?

Peter Joe Pitts’ options cover 900,000 common shares at a $1.00 exercise price and expire on July 24, 2036. The grant is structured as a long-term incentive under the 2014 Stock Incentive Plan, aligning potential value with company performance over time.

How do the BCLI options granted to Peter Joe Pitts vest over time?

The options vest over 48 months, with 25% vesting on July 24, 2027 and the remaining 75% vesting in 1/48th increments monthly. Vesting is conditioned on Peter Joe Pitts remaining employed through each applicable vesting date.

How many BCLI derivative securities does Peter Joe Pitts hold after this grant?

After this transaction, Peter Joe Pitts holds 900,000 stock options linked to Brainstorm Cell Therapeutics common stock. This reflects the full amount of the new grant, as the report shows 900,000 derivative securities owned following the award.

What type of security is involved in the recent BCLI insider transaction?

The transaction involves a Stock Option (Right to Buy) derivative security linked to Brainstorm Cell Therapeutics’ common stock. Each option grants the right to purchase one common share at $1.00, subject to the vesting schedule and expiration terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pitts Peter Joe

(Last)

(First)

(Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽¹⁾	$1	07/24/2026		A		900,000		⁽²⁾	07/24/2036	Common Stock	900,000	$0	900,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Peter J. Pitts	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR